FOSTER CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology...
Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
Apollomics™ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion...
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (€œApollomics€ or the €œCompany€), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Apollomics or the Company), a clinical-stage biopharmaceutical company developing medicines to address...
Treatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification, reflecting œreal-world1 setting FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) --...
Avistone Announces the First Approval of Vebreltinib for MET
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Announces New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib
Avistone Announces Phase II Results for Vebreltinib at ESMO Congress